Update on Placing and Subscription

RNS Number : 6637D

Integumen PLC

11 October 2018

 

11 October 2018

Integumen plc

("Integumen" or "the Company")

Update on Placing and Subscription

The Company provides an update further to the announcement of 27 September 2018.

Funding

As announced on 27 September 2018 the Company has been provided with access to working capital from an unsecured loan facility provided by Cellulac plc with an interest rate of 0% on funds drawn.

It has been agreed in principle by Integumen and Cellulac, that this zero-interest facility is being extended until 30 April 2019 by up to an additional £300,000. Along with funds already loaned to Integumen, the total amount is not expected to exceed £400,000. Further amounts drawn down under the facility will be subject to the same conditions. The funds drawn under this arrangement will not fall as repayable until completion of an alternative funding arrangement or completion of any corporate transaction requiring Integumen shareholders' approval under AIM Rule 14. The Directors intend to draw on the facility as required to meet the Company's ongoing working capital needs.

The above non-dilutive funding facility is taking the place of the second tranches of the Placing and Subscription (previously announced on 16 July 2018, 19 July 2018 and 24 July 2018) which will not now proceed.

Investment in Cellulac

It is expected that completion of Integumen's acquisition of a 9.35% stake  in Cellulac plc will take place shortly. Further details will be notified in due course.

Integumen plc	Gerard Brandon, Chief Executive	[phone]
SPARK Advisory Partners Limited (Nominated Adviser)	Neil Baldwin/Andrew Emmott	[phone]
Hybridan LLP (Broker)	Claire Noyce	[phone]

 

END

 

 

UPDEAPEEFDFPFFF